SOME CHARACTERISTICS OF EDE PATIENTS HAVING COVID-19 AFTER VACCINATION IN DAK LAK, 2021

Nguyễn Ngọc Như Khuê1,, Vũ Thị Quỳnh Hậu2, Nguyễn Hữu Huyên3
1 Tay Nguyen Regional General Hospital
2 Health Center of Buon Ma Thuot
3 Dak Lak Department of Health

Main Article Content

Abstract

The research uses the cross-sectional descriptive method. We collected medical records  information of the 410 Ede patients who had COVID-19 after being vaccinated. The research had some conclusion: The mean age is 36.7 ± 14.6 years old. They are mainly​​ live in rural areas and doing the farming. 74.15% of them know that they had COVID-19 due to infecting resource. The mean duration of treatment was 15.77 ± 2.86 days and 8.29% of patients had comorbidities. 93.17% patients were vaccinated with 1 dose and 6.83% had 2 doses of COVID-19 vaccine. There was a relationship between vaccination status and the diagnosis of asymptomatic and mild COVID-19 patients (p<0.05). 65.37% of patients had the onset of symptoms: cough (76.87%), stuffy nose (49.63%), muscle pain (15.30%), fever (10.07%), loss/change of taste (2.23%) and loss/change of smell (0.75%). The patient’s disease severity on admission was asymptomatic and mild at 34.63% and 61.22%, respectively. The index of red blood cells, white blood cells and platelets of the patient's blood counts during the treatment did not have any abnormalities. There were 18.42% of patients with lung damage among the patients received X-rays. There was a relationship between vaccination and treatment time of patients (p<0.01). 99.51% of patients had stable treatment results and were discharged from hospital. 74.15% of patients were eligible for hospital discharge after the 2nd RT-PCR test results with an average time of 12.4 ± 2.25 days.

Article Details

References

1. Washington State Department of Health; SARS-CoV-2 Vaccine Breakthrough Surveillance and Case Information Resource. https://www.doh.wa.gov/Portals/1/Documents/1600/coronavirus/data-tables/420-339-VaccineBreakthroughReport.pdf. Accessed on 17 12 2021.
2. Lisa Maragakis, Gabor David Kelen; Breakthrough Infections: Coronavirus After Vaccination. https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/breakthrough-infections-coronavirus-after-vaccination. Accessed on 17 12 2021.
3. Sở Y tế Đắk Lắk. Báo cáo nhanh số 715/BC-SYT ngày 12/11/2021 của Sở Y tế Đắk Lắk về tình hình phòng, chống dịch COVID-19 trên địa bản tỉnh Đắk Lắk ngày 13/11/2021.
4. Sheikh A MJ, Taylor B, Robertson C. . SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397: 2461–2.
5. Lopez Bernal J AN, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2012; 385: 585-94.
6. Seppälä E VL, Starrfelt J, et al. Vaccine effectiveness against infection with the delta (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill. 2021;26:2100793.
7. N.V.V. Chau et al. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine 41 (2021) 101143. https://doi.org/10.1016/j.eclinm.2021.101143. Accessed on 04 01 2022.
8. Sở Y tế Đắk Lắk. Báo cáo số 820/BC-SYT ngày 07/12/2021 của Sở Y tế Đắk Lắk về nội dung chất vấn tại kỳ họp thứ 3 của hội đồng nhân dân tỉnh.
9. Bộ Y tế. Quyết định số 4689/QĐ-SYT ngày 06/10/2021 của Bộ y tế về việc ban hành Hướng dẫn chẩn đoán và điều trị COVID-19.
10. Lopez Bernal J, Andrews N, Gower C. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373.